57160
document
Brief Report : social disability in autism spectrum disorder : results from Research Units on Pediatric Psychopharmacology ( RUPP ) Autism Network trials . There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials . We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded , multi-site , randomized trials with risperidone . Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions . Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training . After 8 weeks of treatment , all active treatments were superior to placebo ( effect sizes ranging from 0.42 to 0.65 ) . The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials .
57161
Intervention_Pharmacological
risperidone
57162
Intervention_Control
placebo
57163
Intervention_Pharmacological
risperidone
57164
Intervention_Pharmacological
risperidone only
57165
Intervention_Pharmacological
risperidone
57166
Intervention_Educational
parent training
57167
Outcome_Mental
social disability
57168
Outcome_Mental
social disability
57169
Outcome_Mental
Aberrant Behavior Checklist Social Withdrawal subscale
57170
Outcome_Mental
social disability